Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jeffrey Kirshner MD, FACP, FASCO

Jeffrey J. Kirshner MD, FACP, FASCO

Medical Oncologist, Hematology Oncology Associates of Central New York (HOACNY), East Syracuse, New York

Dr. Jeffrey J. Kirshner is a medical oncologist at Hematology Oncology Associates of Central New York (HOACNY) in East Syracuse and serves as an investigator in the Alliance for Clinical Trials in Oncology. He is an author or co-author of over 75 peer-reviewed research publications. He has an active clinical practice as well, currently specializing in breast cancer.

He received his medical degree from the University of Pennsylvania School of Medicine and completed residency and fellowship training at the SUNY Upstate Medical Center.

Dr. Kirshner has a strong interest in patient care and is actively involved in clinical research. He is also an active volunteer in Alliance and ASCO. He currently serves as the chair of the Data Safety and Monitoring Board for Alliance and is a member of several committees: Breast Committee, Symptom Intervention Committee, and Community Oncology Committee. He is a member of the ASCO Practice Guidelines Implementation Network and serves as the community oncology representative on four expert panels and the Cancer Survivorship Guidelines Advisory Group.

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Oncology: DESTINY-Breast06 — TDX-d for HR+/HER2-Low or HER2 Ultra–Low Breast Cancer After Prior Endocrine Therapy
  2. Ten Practice Changes That I Will Make After Attending ASCO 2024
  3. ASCO 2024: Abstract Recommendations From Dr. Jeffrey Kirshner for Symptoms and Survivorship
  4. Activity and Safety of the Novel Oral Selective Androgen Receptor Modulator Enobosarm in Patients With AR+, ER+, and HER2− Advanced Breast Cancer
  5. 2023 Top Story in Oncology: The PROSPECT Study
  6. ESMO 2023: Recommendations From Dr. Jeffrey Kirshner for Symptoms and Survivorship
  7. Ten Practice Changes I Will Make After Attending ASCO 2023
  8. 2022 Top Story in Oncology: DESTINY-Breast04
  9. Ten Practice Changes That I Will Make After Attending ASCO 2022
  10. ASCO 2022: Abstract Recommendations From Dr. Jeffrey Kirshner for Symptoms and Survivorship

Most Read This Week

Recently Updated